Canadian Journal of Infectious Diseases and Medical Microbiology / 2018 / Article / Tab 2

Review Article

Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli

Table 2

Fosfomycin concentrations in plasma, urine, and prostate following a single 3 g oral dosea.

ParameterMean (±SD)MedianRange

Plasma
 Time after dose (min)565 (149)578.5385–995
 Concentration (μg/mL)11.42 (7.60)10.842.29–40.38
Urine
 Time after dose (min)581 (150)593398–1020
 Concentration (μg/mL)570.57 (418.40)434.8647.99–1522.05
Prostate transition zone
 Time after dose (min)598 (152)598420–1025
 Concentration (μg/g)8.30 (6.63)5.350.56–26.05
Prostate peripheral zone
 Time after dose (min)608 (155)598420–1067
 Concentration (μg/g)4.42 (4.10)2.970.17–18.06
Prostate mean
 Time after dose (min)602.87 (153.36)598420–1046
 Concentration (μg/g)6.50 (4.93)4.670.67–22.06
Prostate/plasma ratio0.67 (0.57)0.500.07–2.92

aData adapted from reference [9]; SD, standard deviation.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.